The global geriatric medicines market size is calculated at USD 181.72 billion in 2025 and is forecasted to reach around USD 348.40 billion by 2034, accelerating at a CAGR of 7.50% from 2025 to 2034. The North America geriatric medicines market size surpassed USD 65.93 billion in 2024 and is expanding at a CAGR of 7.63% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Geriatric Medicines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Geriatric Medicines Market, by Therapeutics Type
8.1.1. Analgesic
8.1.1.1. Market Revenue and Forecast
8.1.2. Antihypertensive
8.1.2.1. Market Revenue and Forecast
8.1.3. Statins
8.1.3.1. Market Revenue and Forecast
8.1.4. Antidiabetic
8.1.4.1. Market Revenue and Forecast
8.1.5. PPI
8.1.5.1. Market Revenue and Forecast
8.1.6. Anticoagulant
8.1.6.1. Market Revenue and Forecast
8.1.7. Antipsychotic
8.1.7.1. Market Revenue and Forecast
8.1.8. Others
8.1.8.1. Market Revenue and Forecast
9.1. Geriatric Medicines Market, by Condition
9.1.1. Cardiovascular
9.1.1.1. Market Revenue and Forecast
9.1.2. Arthritis
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurological
9.1.3.1. Market Revenue and Forecast
9.1.4. Respiratory
9.1.4.1. Market Revenue and Forecast
9.1.5. Osteoporosis
9.1.5.1. Market Revenue and Forecast
9.1.6. Cancer
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. Geriatric Medicines Market, by Distribution Channels Type
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Online Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Forecast
11.1. Geriatric Medicines Market, by Route of Administration Type
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast
11.1.3. Others
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutics
12.1.2. Market Revenue and Forecast, by Condition
12.1.3. Market Revenue and Forecast, by Distribution Channels Type
12.1.4. Market Revenue and Forecast, by Route of Administration Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutics
12.1.5.2. Market Revenue and Forecast, by Condition
12.1.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.1.5.4. Market Revenue and Forecast, by Route of Administration Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutics
12.1.6.2. Market Revenue and Forecast, by Condition
12.1.6.3. Market Revenue and Forecast, by Distribution Channels Type
12.1.6.4. Market Revenue and Forecast, by Route of Administration Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutics
12.2.2. Market Revenue and Forecast, by Condition
12.2.3. Market Revenue and Forecast, by Distribution Channels Type
12.2.4. Market Revenue and Forecast, by Route of Administration Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutics
12.2.5.2. Market Revenue and Forecast, by Condition
12.2.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.2.5.4. Market Revenue and Forecast, by Route of Administration Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutics
12.2.6.2. Market Revenue and Forecast, by Condition
12.2.6.3. Market Revenue and Forecast, by Distribution Channels Type
12.2.6.4. Market Revenue and Forecast, by Route of Administration Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutics
12.2.7.2. Market Revenue and Forecast, by Condition
12.2.7.3. Market Revenue and Forecast, by Distribution Channels Type
12.2.7.4. Market Revenue and Forecast, by Route of Administration Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutics
12.2.8.2. Market Revenue and Forecast, by Condition
12.2.8.3. Market Revenue and Forecast, by Distribution Channels Type
12.2.8.4. Market Revenue and Forecast, by Route of Administration Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutics
12.3.2. Market Revenue and Forecast, by Condition
12.3.3. Market Revenue and Forecast, by Distribution Channels Type
12.3.4. Market Revenue and Forecast, by Route of Administration Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutics
12.3.5.2. Market Revenue and Forecast, by Condition
12.3.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.3.5.4. Market Revenue and Forecast, by Route of Administration Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutics
12.3.6.2. Market Revenue and Forecast, by Condition
12.3.6.3. Market Revenue and Forecast, by Distribution Channels Type
12.3.6.4. Market Revenue and Forecast, by Route of Administration Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutics
12.3.7.2. Market Revenue and Forecast, by Condition
12.3.7.3. Market Revenue and Forecast, by Distribution Channels Type
12.3.7.4. Market Revenue and Forecast, by Route of Administration Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutics
12.3.8.2. Market Revenue and Forecast, by Condition
12.3.8.3. Market Revenue and Forecast, by Distribution Channels Type
12.3.8.4. Market Revenue and Forecast, by Route of Administration Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutics
12.4.2. Market Revenue and Forecast, by Condition
12.4.3. Market Revenue and Forecast, by Distribution Channels Type
12.4.4. Market Revenue and Forecast, by Route of Administration Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutics
12.4.5.2. Market Revenue and Forecast, by Condition
12.4.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.4.5.4. Market Revenue and Forecast, by Route of Administration Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutics
12.4.6.2. Market Revenue and Forecast, by Condition
12.4.6.3. Market Revenue and Forecast, by Distribution Channels Type
12.4.6.4. Market Revenue and Forecast, by Route of Administration Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutics
12.4.7.2. Market Revenue and Forecast, by Condition
12.4.7.3. Market Revenue and Forecast, by Distribution Channels Type
12.4.7.4. Market Revenue and Forecast, by Route of Administration Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutics
12.4.8.2. Market Revenue and Forecast, by Condition
12.4.8.3. Market Revenue and Forecast, by Distribution Channels Type
12.4.8.4. Market Revenue and Forecast, by Route of Administration Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutics
12.5.2. Market Revenue and Forecast, by Condition
12.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.5.4. Market Revenue and Forecast, by Route of Administration Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutics
12.5.5.2. Market Revenue and Forecast, by Condition
12.5.5.3. Market Revenue and Forecast, by Distribution Channels Type
12.5.5.4. Market Revenue and Forecast, by Route of Administration Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutics
12.5.6.2. Market Revenue and Forecast, by Condition
12.5.6.3. Market Revenue and Forecast, by Distribution Channels Type
12.5.6.4. Market Revenue and Forecast, by Route of Administration Type
13.1. GlaxoSmithKline PLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi S.A.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bristol-Myers Squibb Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Boehringer Ingelheim GmbH
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Company Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott Laboratories Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lilly & Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AstraZeneca PLC
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample